Netanel Group: Leumi Partners Buys Time, but Dilution and Interest Set the Cost
The Leumi Partners transaction brought Netanel Group roughly NIS 90 million of cash and financing, but it was not clean equity alone. The package combines shares, three warrant series, full-ratchet protection, an 8% fixed-rate loan and governance rights, so the liquidity relief carries a higher shareholder cost than the headline cash inflow suggests.
Netanel Group received from Leumi Partners exactly what a leveraged residential developer needs during a transition period: time. The private placement and loan package lifted cash and reduced immediate pressure while Modi'in started bringing in buyer advances, but this was not a simple NIS 45 million equity investment plus a comfortable loan. The funding cost sits in three layers: immediate dilution and warrants, a Full Ratchet anti-dilution mechanism that protects the investor against cheaper future issuances, and a five-year loan bearing fixed annual interest of 8%. In residential development, the need for financing is not unusual. What is more decisive here is a package that combines equity, debt, warrants, price protection and governance rights, shifting a larger share of future value toward the new capital provider before existing shareholders see freely accessible project surplus. The transaction can still prove efficient if the capital buys enough time for projects to release cash. It will look more expensive if the cash is absorbed by interest, project equity and operating needs before projects generate enough cash to repay debt and limit potential dilution. The near-term proof point is therefore not the mere entry of Leumi Partners, but whether the time purchased turns into wider covenant headroom and actual project collections.
The Deal Is Not Just Equity, It Is a Rights Package
The straightforward part of the transaction is the placement: 3,024,194 ordinary shares at NIS 14.88 per share, for total proceeds of NIS 45 million. That is important cash for a company whose first quarter still relied on external financing, but it is only one layer of the structure. Alongside the shares, Leumi Partners received three warrant series. For Series B and Series C, the company may choose a cashless exercise mechanism instead of receiving the full exercise price in cash.
| Package component | Economic term | Meaning for existing shareholders |
|---|---|---|
| Ordinary shares | 3,024,194 shares at NIS 14.88 per share | Immediate dilution for NIS 45 million of cash |
| Series A warrants | 3,024,194 five-year warrants at NIS 14.88 exercise price | Potential future dilution if the share price rises above the exercise price |
| Series B warrants | 537,634 five-year warrants at NIS 14.88 exercise price | Possible cashless exercise, so full cash may not enter on exercise |
| Series C warrants | 125,000 five-year warrants at NIS 16 exercise price | Additional warrant layer with cashless exercise possibility |
| Full Ratchet protection | 36 months of protection against issuances below NIS 14.88 | A cheaper future issuance could grant the investor additional shares |
| Loan | NIS 45 million for 5 years at 8% fixed annual interest | NIS 3.6 million annual interest cost and bullet principal repayment |
The Full Ratchet mechanism is what takes the transaction beyond ordinary dilution. If within 36 months the company enters into a transaction that results in an issuance of shares or convertible securities at a price below NIS 14.88 per share, subject to completion of that transaction, the investor will be entitled to additional shares. The employee exception is limited to issuances of up to 3% of issued and paid-up capital and at a price not lower than 85% of the set price. Economically, Leumi Partners is not only investing at a fixed entry price. It receives protection if the company later has to raise capital at a lower price.
The New Capital Creates Breathing Room, but Not All of It Is Clean Equity
In the cash-flow statement, the transaction first appears as a liquidity boost: NIS 45 million of proceeds from securities issuance, NIS 1.1 million of issuance costs, and long-term loan receipts of NIS 86.4 million. Management explains that the increase in cash came mainly from the securities package and a Leumi Partners loan totaling roughly NIS 90 million. That is a clear reason why cash and cash equivalents rose to NIS 127.3 million at the end of March.
But the equity statement and balance sheet show that the package is more complex than cash for shares. The issuance of securities increased equity by NIS 41.9 million, not by the full NIS 45 million. That movement included NIS 3.0 million in share capital, NIS 28.9 million in share premium and NIS 10.0 million of option proceeds. At the same time, the balance sheet recorded a NIS 1.7 million liability for warrants.
That accounting classification matters because it describes part of the package cost, not only technical reporting. Series B and Series C warrants were classified as a financial liability measured at fair value through profit or loss because cashless exercise is possible. Issuance costs allocated to those series were also recognized immediately as an expense, while costs allocated to the shares and Series A warrants were deducted from equity. In other words, part of the transaction's cost can continue to pass through the financial statements after the cash has already entered the company.
The Loan and Governance Rights Decide Who Pays for the Time
The Leumi Partners loan looks comfortable in terms of maturity, because the principal is due in one payment at the end of five years and the company may repay early without penalty or fee. But the cost is not marginal. Fixed annual interest of 8% on NIS 45 million equals NIS 3.6 million per year, with semiannual interest payments beginning on June 30, 2026. For a company that already paid NIS 13.8 million of interest and fees in the first quarter, this adds another fixed-interest layer to an already heavy funding structure.
The governance layer is not cosmetic either. Subject to the investor exercising warrants so that the exercise shares represent at least 2% of the company's capital and holding at least 7.5% of the shares, the controlling shareholder undertook to vote in favor of appointing one director proposed by the investor, with a board of at least five members. Leumi Partners also received tag-along rights on certain sales by the controlling shareholder, subject to defined exceptions. These are not interest-rate terms, but they are part of the capital cost: the investor receives not only potential financial return, but also structural protections around control, exit and dilution.
That is the abnormal feature relative to plain financing for a residential developer. A company in this sector is expected to live with debt, bank facilities and project equity. Here, however, the capital provider receives shares, warrants, price protection, an 8% fixed-rate loan and conditional governance rights at the same time. The package says that the market did not merely provide another cash cushion. It demanded compensation for the risk that the projects still are not releasing cash fast enough for the balance sheet.
The Purchased Time Must Become Project Cash
The Leumi Partners transaction improves liquidity and reduces near-term risk, but it does not erase the cost of capital. The current judgment is positive at the funding-survival level and more difficult at the existing-shareholder economics level. If Modi'in, Beitar and the other projects start returning cash and widening covenant headroom before the interest and warrants become a heavier cost, the package will look like efficient bridge financing. If not, the next few quarters will show that the company bought time through debt, dilution and protections for a new investor, rather than through a fast enough improvement in project cash conversion.
Disclosure: Deep TASE analyses are general informational, research, and commentary content only. They do not constitute investment advice, investment marketing, a recommendation, or an offer to buy, sell, or hold any security, and are not tailored to any reader's personal circumstances.
The author, site owner, or related parties may hold, buy, sell, or otherwise trade securities or financial instruments related to the companies discussed, before or after publication, without prior notice and without any obligation to update the analysis. Publication of an analysis should not be read as a statement that any position does or does not exist.
The analysis may contain errors, omissions, or information that changes after publication. Readers should review official filings and primary sources before making decisions.